|Articles|December 8, 2022

Supplements and Featured Publications

  • Optimizing Outcomes in Venous Thromboembolism Among Hospitalized Medically Ill Patients Through an Integrated Risk Assessment Program

Optimizing Outcomes in Venous Thromboembolism Among Hospitalized Medically Ill Patients Through an Integrated Risk Assessment Program

This publication was supported by Janssen Pharmaceuticals, Inc., and is intended for formulary decision makers, population health decision makers, and/or similar entities.

This AJMC® Profiles in Care is an actionable resource for provider organizations seeking to implement a prevention protocol to reduce the incidence of preventable venous thromboembolism in hospitalized medically ill (nonsurgical) patients.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo